Table 1.
Description of published studies evaluating daptomycin use in orthopedic infections.
| Author | Region | Date | N | Infection (n) | Daptomycin dose (mg/kg) | Length of therapy (days) | Clinical cure rates |
|---|---|---|---|---|---|---|---|
| Chang | Taiwan | 2013–2014 | 16 | KA (9) | 8.3 | 14 | KA (80%) |
| HA (7) | HA 91% | ||||||
| Herrera | Espanha | 2008–2015 | 21 | KA (12) | 10 | 24 | KA (83%) |
| HA (9) | HA (88%) | ||||||
| Jugun | Swiss | 2013 | 16 | OM (10) | 8.15 | 21 | OM (90%) |
| KA (3) | KA (100%) | ||||||
| HA (3) | HA (100%) | ||||||
| Kuo | Taiwan | 2010–2012 | 22 | KA (10) | 6 | 14 | KA (100%) |
| HA (12) | HA (100%) | ||||||
| Lora-Tamayo | Espanha | 2010–2012 | 18 | KA (7) | 10 | 42 | KA (42%) |
| HA (11) | HA (50%) | ||||||
| Byren | Multicenter | 2007–2010 | 47 | KA (27) | 6 e 8 | 24 | KA (59%) |
| HA 20) | HA (42-75%) | ||||||
| Lai | Taiwan | 2007–2009 | 12 | OM/SA (12) | 6, 8 e 10 | – | 91% |
| Moenster | EUA | 2003–2009 | 17 | OM (17) | 5.58 | 14 | 71% |
| Pérez-Cardona | Espanha | 2008–2010 | 20 | KA (7) | 6.6 | 45 | KA (45%) |
| HA (13) | HA (65%) | ||||||
| Lalani | Multicenter | 2002–2005 | 21 | OM (10) | 6 | 23 | SA (64%) |
| SA (11) | OM (70%) | ||||||
| Rao | USA | 2004–2005 | 13 | KA (10) | 4 | 240 | KA (50%) |
| HA (2) | HA (50%) | ||||||
| Sh Ar (1) | Sh Ar (0%) | ||||||
| Finney | USA | 2003–2004 | 10 | OM (6) | – | 24 | OM (100%) |
| SA (4) | SA (75%) |
KA, knee arthroplasty; HA, hip arthroplasty; Sh Ar, shoulder arthroplasty; OM, osteomyelitis; SA, septic arthritis.